论文部分内容阅读
目的观察分析非小细胞肺癌采用培美曲塞联合顺铂治疗的临床效果以及用药后的毒副作用。方法选择我院就诊并确诊为非小细胞肺癌的患者94例,随机分为两组,实验组与对照组,每组47例。实验组采用培美曲塞加顺铂,对照组则使用吉西他滨加顺铂对患者进行化疗。观察两组用药的临床效果及毒副作用。结果两组治疗效果在短期内差异不明显;实验组在恶心、贫血、肝肾功能损害等不良反应方面发生率明显低于对照组(P<0.05);在1、2年生存率的对比中,实验组高于对照组,差异有统计学意义(P<0.05)。结论非小细胞肺癌采用培美曲塞联合顺铂的治疗方案效果良好,不良反应少见,可推广应用。
Objective To observe the clinical effects of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC) and the side effects after treatment. Methods A total of 94 patients with NSCLC who were diagnosed as non-small cell lung cancer in our hospital were randomly divided into two groups: experimental group and control group, with 47 cases in each group. Pemetrexed plus cisplatin was used in the experimental group and gemcitabine plus cisplatin in the control group. The clinical effects and side effects of the two groups were observed. Results There was no significant difference between the two groups in the short term. The incidence of nausea, anemia, liver and kidney dysfunction and other adverse reactions in the experimental group was significantly lower than that in the control group (P <0.05). In comparison with the 1 and 2 year survival rates , The experimental group than the control group, the difference was statistically significant (P <0.05). Conclusion The curative effect of pemetrexed combined with cisplatin in non-small cell lung cancer is good, the adverse reactions are rare, which can be popularized and applied.